Industry

FDA approves Enspryng for thyroid eye disease

Healio Optometry3d ago1 min read

Editor’s note: This is a developing story. Please check back soon for comments.The FDA approved Enspryng, an interleukin-6 inhibitor, for at-home subcutaneous treatment of thyroid eye disease, according to a press release from Genentech.The approval was supported by findings from the phase 3 SatraGO program in thyroid eye disease (TED). In patients with active and chronic moderate to severe TED, the SatraGO-2 trial demonstrated a “significant and clinically meaningful difference” of 52.9% in proptosis response and 60.7% in diplopia reduction with Enspryng vs. 23.4% and 25.8%, respectively, in

Read full article on Healio Optometry

AI Summary

Quick Take

The FDA has approved Genentech’s Enspryng (satralizumab), an interleukin-6 (IL-6) inhibitor, as the first at-home subcutaneous treatment for patients with active and chronic moderate-to-severe thyroid eye disease (TED). Clinical data from the Phase 3 SatraGO-2 trial demonstrated that Enspryng significantly outperformed placebo in reducing both proptosis (52.9% vs. 23.4%) and diplopia (60.7% vs. 25.8%).

Why It Matters

This approval introduces a major shift in the TED treatment paradigm by offering a self-administered subcutaneous option, contrasting with the IV infusion requirements of existing biologics like teprotumumab. By targeting the IL-6 pathway, Enspryng provides a distinct mechanism of action that appears effective in both the active and chronic stages of the disease. For clinicians, this means expanded therapeutic choices and improved convenience for patients who may struggle with the logistics of clinic-based infusions.

Key Findings

In the SatraGO-2 trial, 52.9% of patients treated with Enspryng achieved a proptosis response, compared to 23.4% in the control group.
Diplopia reduction was significantly higher in the Enspryng group at 60.7%, while the control group saw a 25.8% reduction.
The treatment is indicated for patients with moderate-to-severe thyroid eye disease in both active and chronic phases.
Enspryng functions as an interleukin-6 (IL-6) inhibitor, offering a different biological target than current IGF-1R therapies.

Key Details

Enspryng is manufactured by Genentech.
The medication is administered subcutaneously, allowing for at-home use.
Approval was based on the results of the Phase 3 SatraGO clinical program.
The drug specifically targets the IL-6 receptor to manage the symptoms of TED.

Study Snapshot

Design

Phase 3 clinical trial (SatraGO program)

Population

Patients with active and chronic moderate-to-severe thyroid eye disease

Practice Implications

Eye care professionals can now consider a subcutaneous, at-home injection for TED patients, which may improve treatment adherence and accessibility. This option is particularly relevant for patients with moderate-to-severe disease who are either in the active inflammatory phase or the stable chronic phase.

Who's Affected

OphthalmologistsOculoplastic SurgeonsOptometristsEndocrinologistsPractice Owners

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.